19th International Forum on Mood and Anxiety Disorders

VIRTUAL EDITION
22 - 24 July 2021

FINAL PROGRAMME

IFMAD
www.ifmad.org

Organized by AFISM
PCO - Organising Secretariat

Publi Créations
Dear Colleagues & Friends,

This year the IFMAD meeting follows the long dark days of the Covid19 pandemic. The meeting of minds will, as always, give updates on treatment of psychiatric disorders and discuss current controversies maintaining the tradition of free and open discussion with major international experts.

The following topics are discussed:

**Treatment Resistant Depression, Augmentation strategies in MDD, Prevention of suicide, Inflammation and Cognition in Mood and Anxiety Disorders, ADHD in adults, COVID-19 lockdown effects on mental Health, Preventing Illness Progression in Bipolar Disorder, Personalised psychiatry: are we there yet?**

The programme is full and provocative and we will work hard to provide everyone a virtual experience, that will enable you to connect and access the latest research through a new format.

The IFMAD Chairmen
FACULTY

David Baldwin (United Kingdom), Borwin Bandelow (Germany), Bernhard Baune (Germany), Istvan Bitter (Hungary), Philippe Courtet (France), Ted Dinan (United Kingdom), Chiara Fabbri (Italy), Naomi Fineberg (United Kingdom), Philip Gorwood (France), Siegfried Kasper (Austria), Sidney Kennedy (Canada), Anja Lok (The Netherlands), Stuart Montgomery (United Kingdom), Carmen Moreno (Spain), Stefano Pallanti (Italy), Alessandro Serretti (Italy), Marta Torrens Melich (Spain), Eduard Vieta (Spain), Allan Young (United Kingdom)

SCIENTIFIC ADVISERS

David Baldwin (United Kingdom), Borwin Bandelow (Germany), Michael Bauer (Germany), Istvan Bitter (Hungary), Timothy Dinan (United Kingdom), Elias Eriksson (Sweden), Naomi Fineberg (United Kingdom), Sidney Kennedy (Canada), Dusica Lecic Tosevski (Serbia), Aleksander Mathé (Sweden), Hans-Jürgen Möller (Germany), Stefano Pallanti (Italy), Jiri Raboch (Czech Republic), Alessandro Serretti (Italy), Dan J. Stein (South Africa), Dietmar Winkler (Austria), Shigeto Yamawaki (Japan), Joseph Zohar (Israel)

CONTACTS

ORGANISING SECRETARIAT

PUBLI CREATIONS – 74 Boulevard d’Italie
98000 Principality of Monaco
Phone: + 377 97 97 35 55
Email: info@ifmad.org
22 July 2021 - SCIENTIFIC PROGRAMME

13.25 – 13.30 WELCOME
Chairs: S. Kasper (Austria), S. Montgomery (UK), E. Vieta (Spain), A.H. Young (UK)

13.30 – 13.40 RISING STAR ORAL PRESENTATION:
GENETIC VARIATIONS ASSOCIATED WITH TREATMENT RESPONSE IN BIPOLAR DEPRESSION
GERARD ANMELLA (SPAIN)
Chairs: E. Vieta (Spain), A.H. Young (UK)

13.40 – 13.45 Question time and comments by the chairmen

13.45 – 13.55 RISING STAR ORAL PRESENTATION:
THE ROLE OF SEX IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER - FINDINGS FROM A CROSS-SECTIONAL EUROPEAN MULTICENTER STUDY
LUCIE BARTOVA (AUSTRIA)
Chairs: E. Vieta (Spain), A.H. Young (UK)

13.55 – 14.00 Question time and comments by the chairmen

14.00 – 14.20 SE. 01 AN UPDATE ON ANXIETY DISORDERS
BORWIN BANDELOW (GERMANY)
Chairs: S. Kasper (Austria), S. Pallanti (Italy)

14.20 – 14.30 Question time
22 July 2021 - SCIENTIFIC PROGRAMME

14.30 – 14.50
SE. 02 PSYCHOBIOTICS FOR STRESS DISORDER
TED DINAN (UNITED KINGDOM)

Chairs: S. Kasper (Austria), S. Pallanti (Italy)

14.50 – 15.00
Question time

15.00 – 15.20
SE. 03 FUNCTIONAL OUTCOME OF BIPOLAR DISORDERS
ALLAN YOUNG (UNITED KINGDOM)

Chairs: S. Kasper (Austria), S. Pallanti (Italy)

15.20 – 15.30
Question time

15.30 – 15.50
SE. 04 MENTAL HEALTH EFFECTS OF THE COVID – 19 PANDEMIC
CARMEN MORENO (SPAIN)

Chairs: B. Bandelow (Germany), S. Montgomery (UK)

15.50 – 16.00
Question time

16.00 – 16.20
SE. 05 DEPRESSION AS AN EPISODIC CONDITION
PHILIP GORWOOD (FRANCE)

Chairs: B. Bandelow (Germany), S. Montgomery (UK)

16.20 – 16.30
Question time

16.30 – 16.50
SE. 06 ADULT ADHD DIAGNOSIS, COMORBIDITIES AND TREATMENT
STEFANO PALLANTI (ITALY)

Chairs: B. Bandelow (Germany), S. Montgomery (UK)

16.50 – 17.00
Question time
23 July 2021 - SCIENTIFIC PROGRAMME

13.00 – 13.20  SE. 07 TREATMENT RESISTANT DEPRESSION: FINDINGS FROM A EUROPEAN STUDY
SIEGFRIED KASPER (AUSTRIA)
Chairs: D. Baldwin (UK), S. Kennedy (Canada)

13.20 – 13.30  Question time

13.30 – 13.50  SE. 08 PSYCHEDELICS IN PSYCHIATRY
SIDNEY KENNEDY (CANADA)
Chairs: D. Baldwin (UK), S. Kasper (Austria)

13.50 – 14.00  Question time

14.00 – 14.25  SP. 01 SPONSORED SYMPOSIUM (SEE PAGE 10*)
14.25 – 14.40  Question time & Closing remarks

14.40 – 15.00  SE. 09 IMPULSIVE AND COMPULSIVE DISORDERS
NAOMI FINEBERG (UNITED KINGDOM)
Chairs: P. Courtet (France), E. Vieta (Spain)

15.00 – 15.10  Question time
23 July 2021 - SCIENTIFIC PROGRAMME

15.10 – 15.30  
SE. 10 PERSONALISED PSYCHIATRY. ARE WE THERE YET?  
**CHIARA FABBRI (ITALY)**  
*Chairs: P. Courtet (France), E. Vieta (Spain)*

15.30 – 15.40  
Question time

15.40 – 16.00  
SE. 11 HAZARDS IN THE TREATMENT OF ANXIETY AND DEPRESSION: FINDINGS FROM THE NATIONAL CLINICAL AUDIT OF ANXIETY AND DEPRESSION  
**DAVID BALDWIN (UNITED KINGDOM)**  
*Chairs: P. Courtet (France), E. Vieta (Spain)*

16.00 – 16.10  
Question time

16.10 – 16.30  
SE. 12 ARE POLYGENIC RISK SCORES USEFUL FOR TREATMENT CHOICE?  
**ALESSANDRO SERRETTI (ITALY)**  
*Chairs: C. Fabbri (Italy), S. Kasper (Austria)*

16.30 – 16.40  
Question time
24 July 2021 - SCIENTIFIC PROGRAMME

08.45 – 09.30  **STROLLING POSTER SESSION**

*Chairs: L. Bartova (Austria), C. Fabbri (Italy)*

09.30 – 09.50  **SE. 13 PREVENTION OF SUICIDE**

**Philippe Courtet (France)**

*Chairs: C. Fabbri (Italy), A. Serretti (Italy)*

09.50 – 10.00  Question time

10.00 – 10.20  **SE. 14 NOVEL ANTIPSYCHOTICS**

**Eduard Vieta (Spain)**

*Chairs: C. Fabbri (Italy), A. Serretti (Italy)*

10.20 – 10.30  Question time

10.30 – 10.50  **SE. 15 DEPRESSION AND SUBSTANCE USE DISORDERS: STATE OF THE ART**

**Marta Torrens Melich (Spain)**

*Chairs: S. Montgomery (UK), A.H. Young (UK)*

10.50 – 11.00  Question time
11.00 – 11.20  SE. 16 INFLAMMATION IN MOOD AND ANXIETY DISORDER  
**BERNHARD BAUNE (GERMANY)**  
*Chairs: S. Montgomery (UK), A.H. Young (UK)*

11.20 – 11.30  Question time

11.30 – 11.50  SE. 17 TREATMENT OF SCHIZOPHRENIA: IS MONOTHERAPY THE GOLD STANDARD?  
**ISTVAN BITTER (HUNGARY)**  
*Chairs: S. Montgomery (UK), A.H. Young (UK)*

11.50 – 12.00  Question time

12.00 – 12.15  **CLOSING REMARKS - POSTER AWARDS**  
S. Kasper (Austria), S. Montgomery (UK), E. Vieta (Spain), A.H. Young (UK)
Friday, 23rd July 2021

LIVE SPONSORED SYMPOSIUM

Psychiatric emergencies in MDD: what are they and how can we manage them?

The following session are not part of the CME programme, both for UEMS/EAACME procedures. Participants cannot claim credits for attending the following session.

14.00 – 14.05 WELCOME AND INTRODUCTION
PHILIP GORWOOD (FRANCE)

14.05 – 14.15 WHEN AND WHY DO PATIENTS WITH MDD PRESENT WITH A PSYCHIATRIC EMERGENCY?
ANJA LOK (THE NETHERLANDS)

14.15 – 14.25 STRATEGIES FOR THE MANAGEMENT OF PATIENTS WITH MDD IN A PSYCHIATRIC EMERGENCY
PHILIP GORWOOD (FRANCE)

14.25 – 14.35 DISCUSSION AND AUDIENCE Q&A
PHILIP GORWOOD (FRANCE) AND ANJA LOK (THE NETHERLANDS)

14.35 – 14.40 CLOSING REMARKS
PHILIP GORWOOD (FRANCE)

Supported by

Janssen

P.01 CLINICAL MEASUREMENT OF THE TIME TO RE-ORIENTATION IN ELECTROCONVULSIVE THERAPY FOR A DEPRESSIVE EPISODE

Natálie Švecová¹; Anna Sákrová¹; Jozef Buday²; Tadeáš Mareš²; Gabriela Podgorná²; Eva Magyárová²; Jiří Raboch²; Martin Anders²; Jakub Albrecht²

¹Faculty of Arts, Charles University, Prague, Czech Rep.; ²Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Rep.

P.02 THE ROLE OF THE KINDLING MODEL ON THE PREVENTION OF MOOD EPISODES

Tiago Coelho Rocha¹; João Francisco Cunha¹; João Alves Leal¹; Joana de Carvalho Moura¹; Sandra Torres¹; Miguel Esteves Carneiro¹; Sérgio Esteves¹; Andreia Lopes¹

¹Centro Hospitalar Barreiro-Montijo, Barreiro, Portugal

P.03 THE IMPACT OF JOB AND INCOME LOSS ON MENTAL HEALTH OUTCOMES DURING THE COVID-19 PANDEMIC: RESULTS FROM A POPULATION-BASED SURVEY

Carlota de Miquel¹; Joan Domènech-Abella¹; Mireia Felez-Nobrega¹; Paula Cristóbal-Narváez¹; Philippe Mortier²; Gemma Vilagut²; Jordi Alonso²; Josep Maria Haro¹; Beatriz Olaya¹

¹Research, Innovation and Teaching Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain; ²Health Services Research Unit, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
P.04 PREDICTORS OF MDD AND GAD IN PATIENTS AFTER SEVERE BURN TRAUMA

Alena Javurkova1,2; Thea Sedlackova3; Jaroslava Raudenska3,1

1Department of Psychology, Faculty of Arts, Charles University, Prague, Czech Rep.; 2Department of Clinical Psychology, 3rd Faculty of Medicine and University Hospital KV, Charles University, Prague, Czech Rep.; 3Department of Nursing, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Rep.

P.05 INDIRECT COMPARISON ESTIMATING THE BENEFIT OF ESKETAMINE COMPARED TO REAL-WORLD TREATMENT OF TREATMENT RESISTANT DEPRESSION IN GENERAL PSYCHIATRY: PRELIMINARY ANALYSIS

Joachim Morrens1; Albino J Oliveira-Maia2,3; Bruno Falissard4; Siobhán Mulhern Haughey5; Sebastien Barbreau6; Yordan Godinov7; Benoît Rive6

1Janssen EMEA, Beerse, Belgium; 2Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal; 3NOVA Medical School, NMS, Universidade Nova de Lisboa, Lisbon, Portugal; 4Centre de Recherche en Epidemiologie et Santé des Populations, Paris, France; 5Janssen EMEA, Dublin, Ireland; 6Janssen EMEA, Paris, France; 7Janssen EMEA, Sofia, Bulgaria

P.06 A VIRTUAL POSITIVE PSYCHOLOGY BASED INTERVENTION MODEL FOR SOCIAL ANXIETY IN YOUNG ADULTS DURING THE COVID 19 PANDEMIC

Sudha R1; Gayatridevi S1

1Avinashilingam Institute for Home Science and Higher education for Women, Coimbatore, India
P.07 INDIRECT COMPARISON ESTIMATING THE BENEFIT OF ESKETAMINE COMPARED TO DISTINCT REAL-WORLD TREATMENT STRATEGIES FOR TREATMENT RESISTANT DEPRESSION IN GENERAL PSYCHIATRY: PRELIMINARY ANALYSIS

Benoît Rive¹; Albino J Oliveira-Maia²,³; Bruno Falissard⁴; Siobhán Mulhern Haughey⁵; Sebastien Barbreau¹; Joachim Morrens⁷

¹Janssen EMEA, Paris, France; ²Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal; ³NOVA Medical School, NMS, Universidade Nova de Lisboa, Lisbon, Portugal; ⁴Centre de Recherche en Epidemiologie et Santé des Populations, Paris, France; ⁵Janssen EMEA, Dublin, Ireland; ⁶Janssen EMEA, Sofia, Bulgaria; ⁷Janssen EMEA, Beerse, Belgium

P.08 OMEGA 3 FATTY ACIDS AS AN ADJUVANT IN THE TREATMENT OF MAJOR DEPRESSION

Axel Valentino Sambrano Silva¹; Crisálida Domínguez²

¹Private practitioner, Private, Outpatient Care, Caracas, Venezuela; ²LuisRazetti University Hospital, Psychiatry, Puerto La Cruz, Venezuela

P.09 EARLY RISK FACTORS OF ANXIETY DISORDERS: THE MODERATOR ROLE OF GENDER IN THE RELATIONSHIP BETWEEN BEHAVIORAL INHIBITION AND PARENTAL BEHAVIOUR IN PRESCHOOL CHILDREN

Róza Sára Sulyok¹; Mónika Miklósi¹,²

¹Eötvös Loránd university Faculty of Education and Psychology, Doctoral School, Budapest, Hungary; ²Heim Pál National Pediatric Institute, Budapest, Hungary
Save 40%

Please note that fees have been reduced of almost 40% with respect to the original format.

Registrations can be made directly through our website www.ifmad.org/2021/ (on-line payment by credit card is in a secure certificate mode). Please note that registration will only be confirmed once the payment has been received. An invoice, that will serve as a confirmation letter of registration, will be sent to all delegates upon receipt of their payment.

<table>
<thead>
<tr>
<th>FEE</th>
<th>Virtual Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Up to the event</td>
</tr>
<tr>
<td>AREA 1 (High Income countries)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>€ 350</td>
</tr>
<tr>
<td>AREA 2 (Lower and upper middle Income)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>€ 300</td>
</tr>
<tr>
<td>AREA 3 (Low Income)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>€ 250</td>
</tr>
<tr>
<td>TRAINEES / STUDENTS &amp; YOUNG RESEARCHERS&lt;sup&gt;4&lt;/sup&gt;</td>
<td>€ 250</td>
</tr>
</tbody>
</table>

<sup>1</sup> Click here to read the World Bank Country and Lending Classification https://datahelpdesk.worldbank.org/knowledgebase/articles/906519

<sup>2</sup> Please, provide certification.

<sup>3</sup> For each registration a handling fee of 10 € will be applied to cover administrative costs.

<sup>4</sup> All registrations are VAT included.
REGISTRATION FEE INCLUDES

- Access to the Virtual Live Sessions
- Possibility to submit questions (and receive replies) for all sessions
- Access to Poster Sessions
- Access to the participants’ list including contacts (if authorized by the attendee)
- Access to all contents for 6 months after the end of the Conference

CANCELLATIONS AND REFUNDS

Cancellation or modification of registration must be sent in writing to the Organizing Secretariat. Before 31 May 2021 all fees will be refunded minus 40 Euro + VAT for administrative charges. All refunds will be settled after the meeting.
CERTIFICATE OF ATTENDANCE

The certificate of attendance is downloadable from the website [https://ifmad.org/2021/](https://ifmad.org/2021/) using your personal credentials sent by e-mail, starting from **July 26th, 2021** and upon having filled the on line Quality Survey.

For Sponsored Groups: Please note that in order to provide the certificate of attendance to each participant, we need the personal e-mail address.

The Certificate of attendance is only delivered to those having attended the Conference.

DIFFERENTIATED ACCESS

Some contents are dedicated to Healthcare Professionals and cannot be accessed by other professionals. Healthcare Professionals and Pharma Company staff members may access all the content of the platform with the exception of the Press Room.

Patient Associations Representatives may access all the content of the platform with the exception of promotional contents by Pharma Companies and Press Room.

Only Speakers and Poster Presenters can access the Speakers Ready Room.

EUROPEAN ACCREDITATION

The **19th International Forum on Mood and Anxiety Disorders** is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **8 European CME credits (ECMEC®s)**.

The Credits Certificate is delivered to those having attended the Conference and having filled the on line Scientific Questionnaire.

To download your certificate, please log in to the website [https://ifmad.org/2021/](https://ifmad.org/2021/) using the personal log-in credentials sent by e-mail, starting from 6th July, 2021. CME Credits certificates is downloadable up to **17th August, 2021**. After this date, in order to comply with the reporting deadline of UEMS, the CME Credits are no longer downloadable.

For Sponsored Groups: Please note that in order to provide the CME certificate to each participant, we need their personal e-mail address.
HELP DESK
A technical helpdesk is available throughout the live experience.

The secretariat desk will open on Thursday, 22nd July with the following schedule:

- Thursday, 22nd July: 11:30 – 17:00 (CET)
- Friday, 23rd of July: 12:00 – 17:00 (CET)
- Saturday, 24th of July: 08:00 – 12:30 (CET)

Contact details are as follows:

SPEAKERS
Viktoria Zahorszki +36 1 797 3901
Skype: live:.cid.8946de300a3a02b
E – mail: info@ifmad.org

POSTER PRESENTERS and PARTICIPANTS
Daniel Tamas +36 1 797 3901
Skype: live:.cid.a8bbacd5fe3f0e2a
E – mail: info@ifmad.org

LANGUAGE
The official language of the Conference is English. No simultaneous translation is provided.

LIVE QUESTION CHATS AND LIVE POLL
The participation to live question chats and live polls during the live sessions is facultative.
NETWORKING OPPORTUNITIES

In the Networking Lounge you can see who is connected in each moment, chat with the other participants (general chat of the congress). Furthermore, accessing the participants list you may download the virtual “Business Card” of other registered participants who have authorized, as yourself, to share their data. The Business Card includes e-mail and phone number to start, eventually, a personal conversation.

PERSONAL DATA AND LIST OF PARTICIPANTS WITH CONTACT

To allow interaction also after the event with other members of the community we invite you, during the registration process, to accept to be included in the list of participants sharing your contacts details.

- Picture (if provided)
- Surname / Name
- Role
- Department
- Institution / Company and address
- Telephone
- Email
- Website

NB: The mobile phone is used only by the secretariat and will not be published. Only in this case you would see the contact details of other participants who shared this opportunity. At any moment you can access from the platform the page “My Profile” and change the authorization status. Please note that if you do not provide authorization to share your data with the other registered participants you cannot access the data of other participants.
PERSONAL CREDENTIALS

To access the 19th International Forum on Mood and Anxiety Disorders use the credential you received when registering and reconfirmed with the confirmation letter received middle of July. Credentials are strictly personal and you should not share them with colleagues. Free name changes are always possible, please write to info@ifmad.org. Name changes are guaranteed until 15th July and might not be so immediate during the dates of the live. Please note that each set of credential provides ONLY ONE ACCESS to the platform.

PRESENCE CONTROL

The virtual platform allows the Congress Secretariat to follow the path done by each participant within the platform. These data are strictly confidential and is used only for:

- Issue a Certificate of Attendance only to attendees effectively present during the days of the live congress
- Issue CME Credits Certificate to attendees who have effectively followed the sessions

The attendees who have authorized the publication of their data may share them with the relevant sponsor while entering their specific Partner Corporate Page.

VIRTUAL EVENT

The 19th International Forum on Mood and Anxiety Disorders is realized in virtual format. The virtual platform is accessible only for registered participants from 20th July, 2021 to 30th December 2021. As per 20th July, 2021 registered participants may access the:

- Published Poster Presentations in the Poster Lounge Area

Live sessions as per scientific programme will take place on from 22nd July to 24th July 2021. Check the programme for timing. The live sessions are recorded and made available to all registered participants from 24th July, 2021 to 30th December 2021.
SPEAKERS READY ROOM

Only Speakers and Poster Presenters can access the Speakers Ready Room.

Each poster presentation should not exceed 5 minutes. The best 3 posters will receive the Award for Best Poster Presentation and will be published in the Journal of Neuropsychobiology edited by Karger. Winners will be disclosed in the Closing Remarks - Poster Awards session on 24th July at 12.00 (CET). The Poster Award Winners will benefit of recognition on the congress website, post–congress newsletter and a free registration for the 20th International Forum on Mood and Anxiety Disorders.

The Speakers Ready Room would be accessible every day from one hour before the beginning to the end of the live programme. More precisely, the Speakers ready room is available during the following hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 22nd of July</td>
<td>12:30 – 17:00 (CET)</td>
</tr>
<tr>
<td>Friday, 23rd of July</td>
<td>12:00 – 17:00 (CET)</td>
</tr>
<tr>
<td>Saturday, 24th of July</td>
<td>08:00 – 12:30 (CET)</td>
</tr>
</tbody>
</table>

Viktoria Zahorszki  +36 1 797 3901
Skype: live:.cid.8946de3000a3a02b
E – mail: info@ifmad.org
Acknowledgements

The Chairmen of the 19th International Forum on Mood and Anxiety Disorders would like to express their gratitude to

Sponsor
For its contribution to the Congress

janssen
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

Media Partners
For their support

Karger
neurology
19th International Forum on Mood and Anxiety Disorders

Virtual Edition
22 - 24 July 2021

www.ifmad.org